Literature DB >> 14530746

Cell therapy with a tissue-engineered kidney reduces the multiple-organ consequences of septic shock.

H David Humes1, Deborah A Buffington, Liandi Lou, Simin Abrishami, Min Wang, Jun Xia, William H Fissell.   

Abstract

OBJECTIVE: Gram-negative septic shock has a clinical mortality rate approaching 50%. The cause of death is secondary to a systemic inflammatory response syndrome with resulting cardiovascular collapse, ischemic damage to vital organs, and multiple-organ systems failure. Renal tubule cell injury occurs early in septic shock but is not clinically appreciated. Since renal tubule cells appear to play a critical role in the immunoregulation of stress states, renal cell therapy during septic shock may alter the detrimental multiple-organ consequences of systemic Gram-negative infection. The development of a tissue-engineered bioartificial kidney consisting of a conventional hemofiltration cartridge in series with a renal tubule assist device (RAD) containing 109 renal proximal tubule cells may be a new therapeutic approach to this clinical disorder.
DESIGN: Laboratory study.
SETTING: University medical school.
SUBJECTS: Pigs weighing 30-35 kg.
INTERVENTIONS: To assess the effect of the bioartificial kidney and the RAD in septic shock, pigs were administered 30 x 10(10) bacteria/kg body weight of Escherichia coli into the peritoneal cavity and within 1 hr were immediately placed in a continuous venovenous hemofiltration extracorporeal circuit with either a sham RAD without cells or a RAD with cells.
MEASUREMENTS AND MAIN RESULTS: In this animal model, septic shock resulted within hours in acute tubule necrosis in the kidneys of all animals. Renal cell therapy resulted in significantly higher cardiac outputs and renal blood flow rates in treated animals compared with sham controls. RAD treatment also was associated with significantly lower plasma circulating concentrations of interleukin-6 and interferon-gamma compared with sham-treated animals. IL-6 release rates from peripheral blood mononuclear cells isolated from RAD-treated animals were significantly higher after endotoxin stimulation than those isolated from control animals. These physiologic and molecular alterations were associated with nearly a doubling of the average survival time in the RAD-treated group compared with the sham control group.
CONCLUSION: These results demonstrate that renal cell therapy ameliorates cardiac and vascular dysfunction, alters systemic cytokine abnormalities, and improves survival time in a large animal model of Gram-negative septic shock. A cell therapeutic approach with a tissue-engineered bioartificial kidney may be a new treatment modality for this current unmet medical need.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14530746     DOI: 10.1097/01.CCM.0000089644.70597.C1

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  19 in total

Review 1.  Cell therapy, advanced materials, and new approaches to acute kidney injury.

Authors:  Alexander S Yevzlin; H David Humes
Journal:  Hosp Pract (1995)       Date:  2009-12

2.  Continuous hemodiafiltration therapy reduces damage of multi-organs by ameliorating of HMGB1/TLR4/NFκB in a dog sepsis model.

Authors:  Jing Sun; Shaolan Shi; Qun Wang; Kezhou Yu; Rong Wang
Journal:  Int J Clin Exp Pathol       Date:  2015-02-01

3.  Bioengineered Renal Cell Therapy Device for Clinical Translation.

Authors:  Christopher J Pino; Angela J Westover; Deborah A Buffington; H David Humes
Journal:  ASAIO J       Date:  2017 May/Jun       Impact factor: 2.872

Review 4.  Cell-based strategies for the treatment of kidney dysfunction: a review.

Authors:  Christopher J Pino; Alexander S Yevzlin; James Tumlin; H David Humes
Journal:  Blood Purif       Date:  2012-10-24       Impact factor: 2.614

Review 5.  Renal cell therapy and beyond.

Authors:  Joon Ho Song; H David Humes
Journal:  Semin Dial       Date:  2009 Nov-Dec       Impact factor: 3.455

Review 6.  The bioartificial kidney: current status and future promise.

Authors:  H David Humes; Deborah Buffington; Angela J Westover; Shuvo Roy; William H Fissell
Journal:  Pediatr Nephrol       Date:  2013-04-26       Impact factor: 3.714

7.  Bioartificial Renal Epithelial Cell System (BRECS): A Compact, Cryopreservable Extracorporeal Renal Replacement Device.

Authors:  Deborah A Buffington; Christopher J Pino; Lijun Chen; Angela J Westover; Gretchen Hageman; H David Humes
Journal:  Cell Med       Date:  2012-01

Review 8.  The bioartificial kidney in the treatment of acute kidney injury.

Authors:  Joon Ho Song; H David Humes
Journal:  Curr Drug Targets       Date:  2009-12       Impact factor: 3.465

9.  Efficacy and safety of renal tubule cell therapy for acute renal failure.

Authors:  James Tumlin; Ravinder Wali; Winfred Williams; Patrick Murray; Ashita J Tolwani; Anna K Vinnikova; Harold M Szerlip; Jiuming Ye; Emil P Paganini; Lance Dworkin; Kevin W Finkel; Michael A Kraus; H David Humes
Journal:  J Am Soc Nephrol       Date:  2008-02-13       Impact factor: 10.121

Review 10.  Acute kidney injury in the elderly population.

Authors:  Rahmi Yilmaz; Yunus Erdem
Journal:  Int Urol Nephrol       Date:  2009-08-26       Impact factor: 2.370

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.